Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
The summary for the Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed): The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator- initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE. Due to the complex nature of requirements in this FOA (e.g., 1:1 matching funds, resource sharing), applicants are strongly encouraged to communicate with the appropriate NIH Scientific/Research Contact and review online Frequently Asked Questions (FAQs) prior to submitting an application. Staff will be able to advise applicants in determining if their research meets the requirements and objectives of this FOA.
| Federal Grant Title: | Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Food and Nutrition Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-HL-23-019 |
| Type of Funding: | Cooperative Agreement |
| CFDA Numbers: | 93.121, 93.173, 93.233, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.866, 93.867 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | October 6th, 2022 |
| Original Application Deadline: | October 6th, 2022 |
| Posted Date: | July 7th, 2022 |
| Creation Date: | July 7th, 2022 |
| Archive Date: | November 11th, 2022 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | $250,000 |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | July 7th, 2022 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-019.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Epidemiological and Behavioral Research in Oral Health
- • Metagenomic Analyses of the Oral Microbiome
- • Phase Iii Clinical Trials in Oral Infectious Diseases
- More Grants from the National Institutes of Health
- • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)
- • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
- • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...
- • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...